Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20053796 | 0.97 | KMT2A (0.58) | KMT2ALMNACA12CA1CA2 | |
| SCHEMBL13558679 | 0.92 | KMT2A (0.53) | KMT2ALMNACA12CA1CA2 | |
| SCHEMBL2328267 | 0.89 | KMT2A (0.77) | KMT2ALMNANR1I2AHRKCNH3 | |
| SCHEMBL1562316 | 0.89 | KMT2A (0.77) | KMT2ALMNANR1I2AHRKCNH3 | |
| SCHEMBL10912439 | 0.89 | KMT2A (0.77) | KMT2ALMNANR1I2AHRKCNH3 | |
| SCHEMBL7937257 | 0.89 | KMT2A (0.77) | KMT2ALMNANR1I2AHRKCNH3 | |
| SCHEMBL17563553 | 0.89 | KMT2A (0.77) | KMT2ALMNANR1I2AHRKCNH3 | |
| SCHEMBL2238412 | 0.89 | KMT2A (0.77) | KMT2ALMNANR1I2AHRKCNH3 | |
| SCHEMBL11083082 | 0.87 | LMNA (0.56) | KMT2ALMNACA12CA1CA2 | |
| SCHEMBL616128 | 0.87 | KMT2A (0.74) | KMT2ALMNANR1I2AHRKCNH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034955-B2 | High molecular weight nonpolar benzotriazoles | BASF SE (DE) | 2015-05-19 | — | — | US | disclosed |
| US-9034955-B2 | High molecular weight nonpolar benzotriazoles | BASF SE (DE) | 2015-05-19 | — | — | US | disclosed |
| EP-2430089-B1 | HIGH MOLECULAR WEIGHT NON-POLAR BENZOTRIAZOLES | BASF SE (DE) | 2013-07-31 | — | — | EP | disclosed |
| EP-2430089-A2 | HIGH-MOLECULAR NON-POLAR BENZTRIAZOLES | BASF SE (DE) | 2012-03-21 | — | — | EP | disclosed |
| US-20120059095-A1 | HIGH MOLECULAR WEIGHT NONPOLAR BENZOTRIAZOLES | BASF SE (DE) | 2012-03-08 | — | — | US | disclosed |
| US-20120059095-A1 | HIGH MOLECULAR WEIGHT NONPOLAR BENZOTRIAZOLES | BASF SE (DE) | 2012-03-08 | — | — | US | disclosed |
| WO-2010130752-A2 | HIGH-MOLECULAR NON-POLAR BENZTRIAZOLES | BASF SE (DE) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010130752-A2 | HIGH-MOLECULAR NON-POLAR BENZTRIAZOLES | BASF SE (DE) | 2010-11-18 | — | — | WO | disclosed |
| US-5118736-A | Polymer stabilization against actinic radiation | CIBA-GEIGY CORPORATION (US) | 1992-06-02 | — | — | US | disclosed |
| EP-0389428-A2 | N,N-Bis(l-hydroxycarbyloxy-2,2,6,6-tetramethyl-piperidin-4-yl) amino triazines and stabilized compositions | CIBA-GEIGY AG (CH) | 1990-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059095-A1 | HIGH MOLECULAR WEIGHT NONPOLAR BENZOTRIAZOLES | SULT1A1, TPST2, SULT2A1 | KMT2A 255/4885LMNA 3686/4885CA12 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.